

# Soffia Gudbjornsdottir

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5546170/publications.pdf>

Version: 2024-02-01

76  
papers

6,056  
citations

125106

35  
h-index

84171

75  
g-index

77  
all docs

77  
docs citations

77  
times ranked

9460  
citing authors

#	ARTICLE	IF	CITATIONS
1	The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 473-485.	2.2	13
2	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Bladder and Renal Cancer: Scandinavian Cohort Study. <i>Diabetes Care</i> , 2022, 45, e93-e96.	4.3	3
3	Shared etiology of type 1 diabetes and Hashimoto's thyroiditis: a population-based twin study. <i>European Journal of Endocrinology</i> , 2022, 186, 677-685.	1.9	2
4	International comparison of glycaemic control in people with type 1 diabetes: an update and extension. <i>Diabetic Medicine</i> , 2022, 39, e14766.	1.2	28
5	Effect of Diabetes on Morbidity and Mortality in Patients With Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2483-2492.	1.8	8
6	Comparison between data-driven clusters and models based on clinical features to predict outcomes in type 2 diabetes: nationwide observational study. <i>Diabetologia</i> , 2021, 64, 1973-1981.	2.9	19
7	Development and validation of a cardiovascular risk prediction model in type 1 diabetes. <i>Diabetologia</i> , 2021, 64, 2001-2011.	2.9	22
8	Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study. <i>Diabetologia</i> , 2021, 64, 2204-2214.	2.9	9
9	Impact of Socioeconomic Factors and Gender on Refill Adherence and Persistence to Lipid-Lowering Therapy in Type 1 Diabetes. <i>Diabetes Therapy</i> , 2021, 12, 2371-2386.	1.2	5
10	New Diabetes Questionnaire to add patients' perspectives to diabetes care for adults with type 1 and type 2 diabetes: nationwide cross-sectional study of construct validity assessing associations with generic health-related quality of life and clinical variables. <i>BMJ Open</i> , 2020, 10, e038966.	0.8	4
11	Patients With Type 2 Diabetes Have an Increased Demand for Pacemaker Treatment: A Comparison With Age- and Sex-Matched Control Subjects From the General Population. <i>Diabetes Care</i> , 2020, 43, 2853-2858.	4.3	15
12	Renal and Cardiovascular Outcomes After Weight Loss From Gastric Bypass Surgery in Type 2 Diabetes: Cardiorenal Risk Reductions Exceed Atherosclerotic Benefits. <i>Diabetes Care</i> , 2020, 43, 1276-1284.	4.3	43
13	Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. <i>BMJ, The</i> , 2020, 369, m1186.	3.0	63
14	Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study. <i>Diabetes Care</i> , 2020, 43, 1326-1335.	4.3	41
15	Adherence to lipid-lowering therapy and risk for cardiovascular disease and death in type 1 diabetes mellitus: a population-based study from the Swedish National Diabetes Register. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000719.	1.2	7
16	Co-aggregation and heritability of organ-specific autoimmunity: a population-based twin study. <i>European Journal of Endocrinology</i> , 2020, 182, 473-480.	1.9	27
17	Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2769-2775.e4.	2.4	37
18	Quality of life in chronic conditions using patient-reported measures and biomarkers: a DEA analysis in type 1 diabetes. <i>Health Economics Review</i> , 2019, 9, 31.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Health-related quality of life and glycaemic control among adults with type 1 and type 2 diabetes – a nationwide cross-sectional study. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 141.	1.0	36
20	Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. <i>BMJ: British Medical Journal</i> , 2019, 366, l4772.	2.4	69
21	Patient-reported outcome and experience measures for diabetes: development of scale models, differences between patient groups and relationships with cardiovascular and diabetes complication risk factors, in a combined registry and survey study in Sweden. <i>BMJ Open</i> , 2019, 9, e025033.	0.8	22
22	Excess risk of lower extremity amputations in people with type 1 diabetes compared with the general population: amputations and type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000602.	1.2	17
23	Glucagon-Like Peptide 1 Receptor Agonists and Risk of Diabetic Retinopathy Complications: Cohort Study in Nationwide Registers From Two Countries. <i>Diabetes Care</i> , 2019, 42, e92-e94.	4.3	13
24	Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks. <i>Circulation</i> , 2019, 139, 2228-2237.	1.6	305
25	Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 1900-1912.	1.6	108
26	Glycaemic control and excess risk of major coronary events in patients with type 2 diabetes: a population-based study. <i>Open Heart</i> , 2019, 6, e000967.	0.9	5
27	Pros and cons of gastric bypass surgery in individuals with obesity and type 2 diabetes: nationwide, matched, observational cohort study. <i>BMJ Open</i> , 2019, 9, e023882.	0.8	25
28	Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 106-114.	5.5	54
29	Elevations of metabolic risk factors 20 years or more before diagnosis of type 2 diabetes: Experience from the AMORIS study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1419-1426.	2.2	25
30	Short-term progression of cardiometabolic risk factors in relation to age at type 2 diabetes diagnosis: a longitudinal observational study of 100,606 individuals from the Swedish National Diabetes Register. <i>Diabetologia</i> , 2018, 61, 599-606.	2.9	57
31	Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study. <i>BMJ Open</i> , 2018, 8, e020309.	0.8	19
32	A disease-specific questionnaire for measuring patient-reported outcomes and experiences in the Swedish National Diabetes Register: Development and evaluation of content validity, face validity, and test-retest reliability. <i>Patient Education and Counseling</i> , 2018, 101, 139-146.	1.0	30
33	Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. <i>BMJ: British Medical Journal</i> , 2018, 363, k4365.	2.4	248
34	Excess risk of hospitalisation for heart failure among people with type 2 diabetes. <i>Diabetologia</i> , 2018, 61, 2300-2309.	2.9	31
35	Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2018, 379, 633-644.	13.9	888
36	Range of Risk Factor Levels. <i>Circulation</i> , 2017, 135, 1522-1531.	1.6	102

#	ARTICLE	IF	CITATIONS
37	Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 376, 1407-1418.	13.9	880
38	Decreased systolic blood pressure is associated with increased risk of all-cause mortality in patients with type 2 diabetes and renal impairment: A nationwide longitudinal observational study of 27,732 patients based on the Swedish National Diabetes Register. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 226-235.	0.9	2
39	Type 1 diabetes mellitus. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17016.	18.1	790
40	Refill adherence and persistence to lipid-lowering medicines in patients with type 2 diabetes: A nation-wide register-based study. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1220-1232.	0.9	10
41	PCI Versus CABG in Patients With Type 1 Diabetes and Multivessel Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1441-1451.	1.2	21
42	Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 799-807.	5.5	53
43	Glycaemic control and excess risk of major coronary events in persons with type 1 diabetes. <i>Heart</i> , 2017, 103, 1687-1695.	1.2	41
44	Changes in risk factors and their contribution to reduction of mortality risk following gastric bypass surgery among obese individuals with type 2 diabetes: a nationwide, matched, observational cohort study. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000386.	1.2	9
45	Mortality in patients with diabetes mellitus and Addison's disease: a nationwide, matched, observational cohort study. <i>European Journal of Endocrinology</i> , 2017, 176, 31-39.	1.9	23
46	Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer. <i>International Journal of Cancer</i> , 2017, 140, 611-617.	2.3	47
47	Association Between Socioeconomic Status and Mortality, Cardiovascular Disease, and Cancer in Patients With Type 2 Diabetes. <i>JAMA Internal Medicine</i> , 2016, 176, 1146.	2.6	100
48	Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 990-998.	2.2	44
49	What is important for you? A qualitative interview study of living with diabetes and experiences of diabetes care to establish a basis for a tailored Patient-Reported Outcome Measure for the Swedish National Diabetes Register. <i>BMJ Open</i> , 2016, 6, e010249.	0.8	58
50	Indications for Insulin Pump Therapy in Type 1 Diabetes and Associations With Glycemic Control. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 1027-1033.	1.3	15
51	Considerably decreased risk of cardiovascular disease with combined reductions in HbA1c, blood pressure and blood lipids in type 2 diabetes: Report from the Swedish National Diabetes Register. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 268-277.	0.9	22
52	Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 996-1003.	4.3	50
53	The relationship between three eGFR formulas and hospitalization for heart failure in 486 individuals with type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 730-735.	1.7	17
54	Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study. <i>BMJ</i> , 2016, 354, i4070.	3.0	52

#	ARTICLE	IF	CITATIONS
55	Electrical atrial vulnerability and renal complications in type 2 diabetes. Reply to Montaigne D, Coisne A, Sosner P et al [letter]. <i>Diabetologia</i> , 2016, 59, 863-864.	2.9	1
56	Teenagers with poor metabolic control already have a higher risk of microvascular complications as young adults. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 533-536.	1.2	35
57	Teenage girls with type 1 diabetes have poorer metabolic control than boys and face more complications in early adulthood. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 917-922.	1.2	39
58	Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. <i>Diabetologia</i> , 2016, 59, 980-988.	2.9	119
59	Decreased eGFR as a Risk Factor for Heart Failure in 13 781 Individuals With Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 131-136.	1.3	12
60	Impact of ethnicity on progress of glycaemic control in 131 935 newly diagnosed patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. <i>BMJ Open</i> , 2015, 5, e007599-e007599.	0.8	29
61	Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18 168 people with type 1 diabetes: observational study. <i>BMJ, The</i> , 2015, 350, h3234-h3234.	3.0	193
62	Risk factors for atrial fibrillation in type 2 diabetes: report from the Swedish National Diabetes Register (NDR). <i>Diabetologia</i> , 2015, 58, 2259-2268.	2.9	28
63	Impact of Socioeconomic Status on Cardiovascular Disease and Mortality in 24,947 Individuals With Type 1 Diabetes. <i>Diabetes Care</i> , 2015, 38, 1518-1527.	4.3	61
64	Cardiovascular disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: a nationwide, matched, observational cohort study. <i>Lancet Diabetes and Endocrinology,the</i> , 2015, 3, 847-854.	5.5	144
65	Durability of oral hypoglycemic agents in drug naïve patients with type 2 diabetes: report from the Swedish National Diabetes Register (NDR). <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000059.	1.2	17
66	Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study. <i>Lancet Diabetes and Endocrinology,the</i> , 2015, 3, 876-885.	5.5	69
67	Excess Body Weight and Cancer Risk in Patients with Type 2 Diabetes Who Were Registered in Swedish National Diabetes Register – Register-Based Cohort Study in Sweden. <i>PLoS ONE</i> , 2014, 9, e105868.	1.1	11
68	Health Utilities of Type 2 Diabetes-Related Complications: A Cross-Sectional Study in Sweden. <i>International Journal of Environmental Research and Public Health</i> , 2014, 11, 4939-4952.	1.2	22
69	Diabetes care – improvement through measurement. <i>Diabetes Research and Clinical Practice</i> , 2014, 106, S291-S294.	1.1	90
70	The triglycerides-to-HDL-cholesterol ratio and cardiovascular disease risk in obese patients with type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR). <i>Diabetes Research and Clinical Practice</i> , 2014, 106, 136-144.	1.1	44
71	Fructosamine Is a Useful Indicator of Hyperglycaemia and Glucose Control in Clinical and Epidemiological Studies – Cross-Sectional and Longitudinal Experience from the AMORIS Cohort. <i>PLoS ONE</i> , 2014, 9, e111463.	1.1	55
72	Trends in blood pressure control in patients with type 2 diabetes – Data from the Swedish National Diabetes Register (NDR). <i>Blood Pressure</i> , 2011, 20, 348-354.	0.7	57

#	ARTICLE	IF	CITATIONS
73	Decreased Muscle Capillary Permeability Surface Area in Type 2 Diabetic Subjects. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1078-1082.	1.8	50
74	Direct Measurements of the Permeability Surface Area for Insulin and Glucose in Human Skeletal Muscle. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4559-4564.	1.8	67
75	The National Diabetes Register in Sweden: An implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care, 2003, 26, 1270-1276.	4.3	199
76	The Effect of Metformin and Insulin on Sympathetic Nerve Activity, Norepinephrine Spillover and Blood Pressure in Obese, Insulin Resistant, Normoglycemic, Hypertensive Men. Blood Pressure, 1994, 3, 394-403.	0.7	76